Minoxidil for facial & hair growth

By uriel
published 2026-09-08

Abstract

Minoxidil is a medication that was originally developed as an antihypertensive, but was later discovered to promote hair growth and prevent hair loss. It exists in two forms: topical (Gupta et al., 2022) and oral (Gupta et al., 2023), both of which can be used to increase body and/or facial hair. This review provides general information; an overview of the main studies evaluating efficacy; an update on the safety of oral minoxidil in light of the clinical evidence; practical information on sourcing and usage; and a comparison of the two forms. For further information on the use of minoxidil for hair loss, see the TFS article on hair loss.

Editor’s Note

This post is a translation of the article Le minoxidil pour la pilosité originally in French with some additional DIY and international related details.

Translation by Ari and uriel, with initial pass by alix using gemma 4 open-weight LLM, run on local hardware. Our em-dashes are certified organic.

Topical Minoxidil

General Overview

Topical minoxidil comes as a spray or foam meant to be applied to the areas where hair growth is desired (typically the scalp or face).

It can be used by anyone: individuals with no facial hair who are not taking testosterone (for example, transmasculine people not taking T), individuals with some facial hair who want to develop it further (with or without T), individuals with otherwise well-developed facial hair who want to fill in patches in their beard, etc.

For individuals on T, the effect of minoxidil is thought to be permanent. For people not on T, it’s less clear: hair would not be expected to fall out upon stopping minoxidil, but it is suspected that it will revert to vellus hair rather than remain as terminal hair. Effects may appear in as little as a few weeks, but this depends on the individual and their hormonal context.

Some people show little to no response to topical minoxidil, likely because they lack an enzyme, sulfotransferase, which has been implicated in its mechanism of action. In such cases, the activity of this enzyme—and thus the efficacy of topical minoxidil—can be increased by using local tretinoin (prescription only) (Ferry et al., 1990; Sharma et al., 2019; Shin et al., 2007).

Topical minoxidil is very safe, and few side effects are reported. Irritation, itching, or redness may occur in the application area. In such cases, a single application per day and/or the use of the foam formulation may be preferred.

Studies

There are still relatively few studies on the use of topical minoxidil for hair growth, and they focus on facial rather than body hair. In addition to case studies (Pang et al., 2021; Shokravi & Zargham, 2024) and some articles on eyebrows, the following clinical trials have been published:

In Practice

Topical minoxidil is available without a prescription from pharmacies in much of the world. The cost varies but it tends to be relatively cheap (approximately <10€ monthly for liquid in the EU for instance) - the foam formulation is typically more expensive.

For facial hair, 5% minoxidil (of any brand) is used applied once or twice daily. Sufficient coverage of the beard area typically requires ~1mL/6 pumps; refer to the dose indicated on the package leaflet.

To give the medication time to penetrate into the hair follicles, wait at least a few hours before rinsing the area. Do not attempt to dry the area after application. Do not mix the minoxidil solution with lotion, or apply lotion just before applying minoxidil, as this can limit absorption.

Minoxidil is very toxic to pets, so care must be taken to prevent any exposure to or ingestion of the medicaiton. For example, if you apply minoxidil to your face, do not allow your pet to rub against or lick the area of application. Keep any contaminated clothes, towels, or bedding away from pets.

Oral Minoxidil

General Overview

Oral minoxidil comes in the form of tablets designed to be swallowed. It may increase the development of both facial and body hair; the effect is not localized. Efficacy also depends on the dose; while there will always be variation between invidivuals, in general a higher dose will have a greater effect on hair growth. For preventing hair loss, a lower dose is often sufficient. When choosing a dose of oral minoxidil, the goal is to find a balance between desired effects and side effects.

Oral minoxidil can be used by anyone, with or without testosterone. As with the topical version, it is likely the effect will be less pronounced and potentially less permanent without testosterone.

Safety

Oral minoxidil is very safe; data now show that the use of low-dose oral minoxidil has a very favorable risk profile, as confirmed by a recent meta-analysis of 27 studies with a total of nearly 3,000 people (Liu et al., 2025).

One of the studies in this meta-analysis, which alone included over a thousand people (Vañó-Galván et al., 2021), had only a ~1% discontinuation rate for oral minoxidil due to side effects (excluding hypertrichosis, i.e. increased hair growth, as this is desirable in the context of this article). Systemic side effects were reported in 5.5% of participants, all of which resolved upon discontinuation or dose reduction. There were no life-threatening side effects. Among the rare reported side effects were dizziness, water retention, and tachycardia.

Should any of these side effects occur, they can often be improved simply by reducing the dose of oral minoxidil. For dizziness in particular, taking minoxidil at bedtime may be preferable. A significant drop in blood pressure is not expected, at least with lower dosages (Desai et al., 2024; Ong et al., 2024b). There may be differences in side effects between cis men and women (Ong et al., 2024a) according to some studies, but it is unclear how these risks might differ in trans people on HRT.

One study observed comparable safety of oral minoxidil use in individuals with cardiovascular problems (hypertension and arrhythmias) as in healthy people (Jimenez-Cauhe et al., 2024). Safety has also been found to be acceptable in children and adolescents, at least for low doses (Williams et al., 2024).

It should be noted that the studies cited here primarily used relatively low doses of oral minoxidil (5mg or less, sometimes 2.5mg or less), and their conclusions are not necessarily applicable to more intermediate doses of 5-10mg, which may be more suitable for hair growth. That said, some reassuring data exist for these dosages as well (Moreno-Arrones et al., 2025; Sanabria et al., 2024). The doses of oral minoxidil used to treat hypertension, its usual clinical indication, are typically even higher (10-40mg, sometimes more).

Studies

There are still relatively few studies on the use of oral minoxidil for hair growth. However, some information can be gleaned from reports of side effects of oral minoxidil used for hair loss, where hypertrichosis is considered undesirable.

The following studies contain relevant information on the use of oral minoxidil for hair growth:

In Practice

Oral minoxidil is typically available only with a prescription. It is also commonly available at grey market online pharmacies. Its cost varies but it tends to be cheap (approximately 10-20$ monthly).

The use of minoxidil for androgenetic alopecia is not very common outside of North America, and even less common for hair growth. It is possible that your doctor may not be familiar with this usage; do not hesitate to insist and show them this article if necessary!

There are several brands of oral minoxidil, formulated as 5 or 10mg tablets, as well as compounded options. The dosage must be adjusted according to the desired effects and, if necessary, side effects. Based on the studies and expert opinions cited previously, it is advisable to start with 2.5-5 mg/day with a possible increase up to 10mg per day if the medication is tolerated well.

As the half-life of oral minoxidil is not very long, it may be taken in two doses over the course of the day (once in the morning and once in the evening), but this is not strictly necessary and one dose per day is sufficient for hair growth.

Specific monitoring is not indicated by the literature, but routine blood pressure measurements seem reasonable, especially in case of pre-existing blood pressure problems or use of high doses of oral minoxidil (≥7.5mg). Because the effect on blood pressure is quick, you can measure it before and 2 hours after a dose (Olsen et al., 2025).

Specific considerations if DIYing

You probably shouldn’t use minoxidil without medical supervision if you have congestive heart failure, ischemic heart disease, pheochromocytoma or renal failure. In general, exercise caution when using oral minoxidil if you have any major cardiac condition or medical condition causing low blood pressure. In particular, titrate up slowly and discontinue use if you get tachycardia, dizziness, etc.

A more exhaustive list of relevant conditions and guidelines on safer use is available in Olsen et al. (2025 Table 2).

Be aware minoxidil may require caution when taken with other blood pressure-lowering medication. If it makes you dizzy, exercise caution when taking sedative medications. You can check a non-exhaustive list of medications oral minoxidil may interact with here.

While it’s typically fine not to mention HRT to doctors when going in for an unrelated health issue or surgery, it’s probably a good idea to mention you’re taking oral minoxidil if you’re seeing a doctor for anything cardiovascular, general anesthesia, etc. Make sure they understand you’re talking about oral minoxidil, and not over-the-counter topical minoxidil. This shouldn’t out you, because oral minoxidil is used by both cis men and cis women, mostly to treat hair loss.

Comparison

Topical Oral
Over-the-counter Prescription/DIY only
Localized effect Whole-body effect
only affects the site of application effective against androgenetic alopecia
must take precautions if interacting with pets no risk for pets
possibility of local side effects (irritation, itching, redness, …) low possibility of systemic side effects (dizziness, water retention, tachycardia, …)

Bibliography

Desai, D., Nohria, A., Sikora, M., Mandal, S., Shapiro, J., Caplan, A. S., Garshick, M., & Lo Sicco, K. (2024). Response to Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study.” Journal of the American Academy of Dermatology, 91(1), e11–e12. https://doi.org/10.1016/j.jaad.2024.01.089
Ferry, J. J., Forbes, K. K., VanderLugt, J. T., & Szpunar, G. J. (1990). Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clinical Pharmacology & Therapeutics, 47(4), 439–446. https://doi.org/10.1038/clpt.1990.55
Gupta, A. K., Talukder, M., Shemar, A., Piraccini, B. M., & Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders, 9(6), 423–437. https://doi.org/10.1159/000531890
Gupta, A. K., Talukder, M., Venkataraman, M., & Bamimore, M. A. (2022). Minoxidil: A comprehensive review. Journal of Dermatological Treatment, 33(4), 1896–1906. https://doi.org/10.1080/09546634.2021.1945527
Ingprasert, S., Tanglertsampan, C., Tangphianphan, N., & Reanmanee, C. (2016). Efficacy and safety of minoxidil 3% lotion for beard enhancement: A randomized, double-masked, placebo-controlled study. Journal of Dermatology, 43(8), 968–969. https://doi.org/10.1111/1346-8138.13312
Jimenez-Cauhe, J., Pirmez, R., Müller-Ramos, P., Melo, D. F., Ortega-Quijano, D., Moreno-Arrones, O. M., Saceda-Corralo, D., Gil-Redondo, R., Hermosa-Gelbard, A., Dias-Sanabria, B., Restom, D., Porriño-Bustamante, M. L., Pindado-Ortega, C., Berna-Rico, E., Fernandez-Nieto, D., Ramos, M., Jaen-Olasolo, P., & Vaño-Galvan, S. (2024). Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermo-Sifiliográficas, 115(1), 28–35. https://doi.org/10.1016/j.ad.2023.07.019
Jimenez-Cauhe, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O. M., Gil-Redondo, R., Ortega-Quijano, D., Fernandez-Nieto, D., Jaen-Olasolo, P., & Vaño-Galvan, S. (2021). Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss. Journal of the American Academy of Dermatology, 84(1), 222–223. https://doi.org/10.1016/j.jaad.2020.08.124
Liu, C., Liu, X., Shi, T., Wang, Y., Sui, C., Zhang, W., & Wang, B. (2025). Efficacy and safety of oral minoxidil in the treatment of alopecia: A single-arm rate meta-analysis and systematic review. Frontiers in Pharmacology, 16, 1556705. https://doi.org/10.3389/fphar.2025.1556705
Lueangarun, S., Panchaprateep, R., & Tempark, T. (2025). Characteristics of Hypertrichosis Induced by 24-week Low-dose (5 mg Daily) Oral Minoxidil in Male Pattern Hair Loss Treatment. International Journal of Trichology, 17(3), 215–220. https://doi.org/10.4103/ijt.ijt_55_24
Marinelli, L., Bichiri, A., Cagnina, S., Castella, L., Ghigo, E., & Motta, G. (2024). Efficacy of topical minoxidil in enhancing beard growth in a group of transgender assigned female at birth individuals on gender affirming hormone therapy. Journal of Endocrinological Investigation, 47(11), 2843–2850. https://doi.org/10.1007/s40618-024-02373-8
Moreno-Arrones, O. M., Hermosa-Gelbard, A., Saceda-Corralo, D., Jimenez-Cauhe, J., Ortega-Quijano, D., Pirmez, R., & Vañó-Galván, S. (2025). [Translated article] High-dose Oral Minoxidil for the Treatment of Androgenetic Alopecia. Actas Dermo-Sifiliográficas, 116(7), T769–T772. https://doi.org/10.1016/j.ad.2025.05.018
Olsen, E. A., Sinclair, R., Hordinsky, M., Mesinkovska, N. A., Sadick, N., Shapiro, J., & Bergfeld, W. (2025). Summation and recommendations for the safe and effective use of topical and oral minoxidil. Journal of the American Academy of Dermatology, 93(2), 457–465. https://doi.org/10.1016/j.jaad.2025.04.016
Ong, M. M., Do, H., Ho, B., & Lipner, S. R. (2024a). Gender differences in adverse effects and dosing practices of low-dose oral minoxidil for androgenetic alopecia: A retrospective analysis of 310 patients. Skin Appendage Disorders, 11(3), 227–231. https://doi.org/10.1159/000542630
Ong, M., Do, H., Ho, B., & Lipner, S. R. (2024b). Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study. Journal of the American Academy of Dermatology, 90(2), 425–427. https://doi.org/10.1016/j.jaad.2023.10.010
Pang, K. C., Nguyen, T. P., & Upreti, R. (2021). Case Report: Successful Use of Minoxidil to Promote Facial Hair Growth in an Adolescent Transgender Male. Frontiers in Endocrinology, 12, 725269. https://doi.org/10.3389/fendo.2021.725269
Ramos-Rodriguez, D., Sanchez-Baez, D., Cabrera-Garcia, P., Perez-Bustillo, A., Hermosa-Gelbard, A., Vaño-Galvan, S., Saceda-Corralo, D., & Jimenez-Cauhe, J. (2026). Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review. Dermatology and Therapy, 16(5), 2343–2362. https://doi.org/10.1007/s13555-026-01735-9
Ramos-Rodríguez, D., Sanchez-Baez, D., Garcia, P. C., Hermosa-Gelbard, A., Saceda-Corralo, D., Vaño-Galvan, S., & Jimenez-Cauhe, J. (2025). Use of oral minoxidil for androgenetic alopecia in transgender and gender-diverse people. A retrospective study of 27 patients. Journal of the American Academy of Dermatology, S0190962225026891. https://doi.org/10.1016/j.jaad.2025.08.061
Sanabria, B. D., Perdomo, Y. C., Miot, H. A., & Ramos, P. M. (2024). Oral minoxidil 7.5 mg for hair loss increases heart rate with no change in blood pressure in 24 h Holter and 24 h ambulatory blood pressure monitoring. Anais Brasileiros de Dermatologia, 99(5), 734–736. https://doi.org/10.1016/j.abd.2023.08.016
Sharma, A., Goren, A., Dhurat, R., Agrawal, S., Sinclair, R., Trüeb, R. M., Vañó-Galván, S., Chen, G., Tan, Y., Kovacevic, M., Situm, M., & McCoy, J. (2019). Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy, 32(3). https://doi.org/10.1111/dth.12915
Shin, H. S., Won, C. H., Lee, S. H., Kwon, O. S., Kim, K. H., & Eun, H. C. (2007). Efficacy of 5% Minoxidil versus Combined 5% Minoxidil and 0.01% Tretinoin for Male Pattern Hair Loss: A Randomized, Double-Blind, Comparative Clinical Trial. American Journal of Clinical Dermatology, 8(5), 285–290. https://doi.org/10.2165/00128071-200708050-00003
Shokravi, A., & Zargham, H. (2024). Facial hair enhancement with minoxidil—an off-label use. SAGE OPEN Medical Case Reports, 12, 2050313X241231490. https://doi.org/10.1177/2050313X241231490
Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., Moreno-Arrones, Ó. M., Saceda-Corralo, D., Rodrigues-Barata, R., Jimenez-Cauhe, J., Koh, W. L., Poa, J. E., Jerjen, R., Trindade De Carvalho, L., John, J. M., Salas-Callo, C. I., Vincenzi, C., Yin, L., Lo-Sicco, K., Waskiel-Burnat, A., Starace, M., Zamorano, J. L., … Bhoyrul, B. (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology, 84(6), 1644–1651. https://doi.org/10.1016/j.jaad.2021.02.054
Wattanawinitchai, K., Pomsoong, C., Ratanapokasatit, Y., & Suchonwanit, P. (2026). Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: A randomized, double-blind, placebo-controlled trial. Journal of Dermatological Treatment, 37(1), 2638637. https://doi.org/10.1080/09546634.2026.2638637
Williams, K. N., Olukoga, C. T. Y., & Tosti, A. (2024). Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review. Dermatology and Therapy, 14(7), 1709–1727. https://doi.org/10.1007/s13555-024-01197-x
Zaminski, D., Zampella, J. G., Shapiro, J., Lo Sicco, K. I., & Mazori, D. R. (2025). Use of low-dose oral minoxidil for hair growth in transgender and gender nonbinary adult patients: A retrospective cohort study. Journal of the American Academy of Dermatology, 93(4), 1126–1129. https://doi.org/10.1016/j.jaad.2025.06.029